Vikram Sahni, MD
Pulmonary Disease · Portland, ORNPI 1932302890
Payments from drug & device makers
What this record shows
This record is dominated by education: $3,000 of the $4,679 with a category attached, or 64.1%. Intuitive Surgical accounts for 89.1% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2023 at $4,175 and has fallen 97.5% since, to $106 in 2024.
Across 16 payments — averaging $292.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$4K
- Amgen$180
- Pulmonx Corporation$177
- AstraZeneca$56
- Regeneron Healthcare Solutions, Inc.$30
- Baxter Healthcare$25
- plus $40 from 2 others
What the payments were for
- Travel & lodging$1,09523%
- Food & beverage$58312%
- Education$3,00064%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 8 | $4,170 |
| Amgen | 1 | $180 |
| Pulmonx Corporation | 1 | $177 |
| AstraZeneca | 2 | $56 |
| Regeneron Healthcare Solutions, Inc. | 1 | $30 |
| Baxter Healthcare | 1 | $25 |
| GSK | 1 | $21 |
| Mylan Specialty L.p. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ION$3,000
- Da Vinci Surgical System$1,057
- TEZSPIRE$180
- Pulmonx Endobronchial Valve EBV$177
How this compares
$4,679 in reported general payments places this provider in the 80th percentile of 154 pulmonary disease providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 26 | $342,719 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 188 | $156,034 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 12 | $114,996 |
| Spiriva RespimatTiotropium Bromide | 98 | $64,980 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 65 | $48,058 |
| NucalaMepolizumab | 13 | $43,270 |
| Breo ElliptaFluticasone/Vilanterol | 101 | $43,060 |
| Qvar RedihalerBeclomethasone Dipropionate | 47 | $17,087 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 40 | $16,503 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 69 | $12,673 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 19 | $9,574 |
| SymbicortBudesonide/Formoterol Fumarate | 36 | $9,473 |
| Advair HfaFluticasone Propion/Salmeterol | 19 | $9,001 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 213 | $7,841 |
| Montelukast Sodium | 257 | $3,392 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Nucala, Breo Ellipta, Anoro Ellipta | $21 | $251,938321 claims |
| AstraZenecaSymbicort | $56 | $9,47336 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 154 pulmonary disease providers in Oregon.
Other pulmonary disease in Portland
- Stephen YauPortland$984K
- Matthew DrakePortland$135K
- Peter LeePortland$98K
- Jordan FeinPortland$87K
- Granthem FarrPortland$66K
- David HotchkinPortland$65K
- Jeffrey RobinsonPortland$51K
- Steven SearsPortland$21K
- Melvin MorganrothPortland$14K
- Christina MacrostyPortland$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.